The therapeutic management of inflammatory disease (ID) represents the perfect scenario for drug targeting to the site(s) of action. While existing formulation-based targeting strategies include dosage forms and oral systems that target the organs by pH-, time-, microflora-, and pressure-triggered drug release, novel approaches for site-specific delivery in ID therapy will target the inflamed organs per se. The therapy of ID is dominated by the administration of anti-inflammatory and immunosuppressive drugs, which suppress the inflammatory burden and improve the disease-related symptoms. Established treatment strategies are characterized by a limited therapeutical efficacy and the occurrence of adverse drug reactions. Thus, the development of novel disease-targeted drug delivery strategies is intended for a more effective therapy and demonstrates the potential to address unmet medical needs. Although various complementary and conventional treatment strategies have been incorporated into experimental and clinical practices, the relevant molecular mechanisms are still under investigation. So, we invite researchers to contribute original research articles as well as review articles that provide solid evidence to support the application of innovative drugs in prevention and treatment of inflammatory diseases.

Potential topics include, but are not limited to:

• Recent advance in identifying active ingredients of nutritional and medicinal herbs against inflammatory diseases
• Experimental and clinical trials of novel drugs on therapeutic treatments of cardiovascular diseases
• Current applications of natural drugs or plant extracts in treatment of cerebral and coronary thrombosis using in vitro and in vivo models
• Advances in revealing acting targets of bioactive compounds for the treatment of cancer, aging, and type 2 diabetes diseases
• Nutritional features of metabolic inflammation in association to health insights for biomarkers in inflammatory diseases
• Role of natural drugs in alleviating the oxidative stress, ROS, and organ inflammation
• Association of MAPK signaling pathway and the downstream transcriptional factors NF-κB with anti-inflammatory treatment strategy